HIV-infected patients on antiretroviral therapy (ART) may present low-level viremia (LLV) above the detection level of current viral load assays. In many cases LLV is persistent but does not result in overt treatment failure or selection of drug resistant viral variants. To elucidate whether LLV reflects active virus replication, we extensively sequenced pol and env genes of the viral populations present before and during LLV in 18 patients and searched for indications of genetic evolution. Maximum likelihood phylogenetic trees were inspected for temporal structure both visually and by linear regression analysis of root-to-tip and pairwise distances. Viral coreceptor tropism was assessed at different time points before and during LLV. In none of the patients consistent indications for genetic evolution were found over a median period of 4.8 years of LLV. As such these findings could not provide evidence that active virus replication is the main driver of LLV.
randomized, double-blind, placebo-controlled study of Hatano et al. in 2013 [21] , addition of raltegravir to a stable ART regimen resulted in a transient increase in 2-LTR circles in 9 of 16 patients.
Other studies, however, failed to confirm this effect of treatment intensification [20, 22] . Today, the hypothesis that the most important sources of residual viremia are long-lived cells that continuously express virus or latently infected cells that produce virus when they become activated while the presence of ART prevents further replication of this virus is gaining more and more acceptance [12, 13] .
While a multitude of studies have investigated the role of virus replication in patients on ART with undetectable VL, studies on the sources of LLV above the detection limit of VL assays are limited and the conclusions from these studies even more contradicting [7, 15, 23] . Anderson et al. and Mens et al. failed to provide proof of ongoing replication, while Tobin et al. did report evidence of genetic evolution of plasma virus in a minority of the studied patients (3 of 11) . Two studies suffered from a low sample number with respectively 1 and 11 LLV individuals included [7, 23] . The extent of patient to patient differences in causes of LLV is unknown and it is also unclear whether virus production on its own can result in plasma virus concentrations above the cut-off levels of currently applied routine VL assays.
In the current study, we searched for signs of viral replication and evolution in 18 patients with persisting LLV. Important added values of this work are the fact that both the plasma and cellular compartments of the blood were investigated and that samples were collected over a long period of time at multiple time points during LLV as well as before initiation of the ART regimen under which LLV manifested. The results of extensive phylogenetic analysis could not provide consistent proof of virus replication.
METHODS

Patient selection
From January 1997 to December 2012, 1393 HIV-infected patients were followed at Ghent University Hospital and 621 were on ART during this period. Persisting LLV was retrospectively detected in a subpopulation of 71 patients. We defined PLLV as a VL between 20 and 250 copies (c)/mL for at least half of minimum 6 VL measurements from six months after the initiation of ART until study inclusion (January 2013) [1] . The VL was determined with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test v2 (Roche, Basel, Switzerland; limit of detection: 20 c/mL). Longitudinal sequence analysis during LLV was attempted for 28 patients randomly selected from the PLLV patients. Extensive phylogenetic and sequence analysis was then performed on the 18 patients for whom at least 3 env and pol sequences were obtained.
All analyses were performed retrospectively on stored plasma and buffy coat samples. The treating clinicians of the included patients were free to adapt the ART regimen during LLV. All patients received intensive individual counselling, including guidance on adherence, food restrictions and interference with other products, in order to exclude potential sources of reduced exposure to ART.
Study design
To be able to amplify and sequence two regions of the HIV genome (pol and env) from samples with very low viral load, an ultrasensitive Sanger sequencing protocol was developed and used for all plasma samples collected during LLV. For the samples collected pre-ART, standard population Sanger sequencing was performed. In-depth characterization of the virus population present at initiation of ART was done by next generation sequencing (NGS) of the last plasma sample collected before starting ART (baseline sample).
Because of expected low concentrations of viral DNA in blood cells collected on ART and because a
longer sequence length allows better identification and elimination of sequences from defective viruses, limiting dilution sequencing was chosen over NGS for characterization of the HIV DNA genetic variability. This limiting dilution DNA sequencing was only preformed for a selection of 8 patients with LLV of over at least 5 years and for whom buffy coat samples were available from at least 3 time points with an interval of 2 years.
Sequencing of HIV-1 pol and env gene fragments
Standard Sanger sequencing of viral RNA
HIV-1 RNA was extracted from EDTA plasma using the High Pure Viral RNA kit (Roche, Basel, Switzerland) according to the manufacturer's instructions. For samples with a VL of <10,000 c/mL, 500 µL of plasma was ultracentrifuged for 1 hour (23,600 × g at 4 °C), after which the pellet was suspended in 200µL of phosphate buffered saline (PBS). For samples with a VL of >10,000 c/mL, RNA was extracted from 200 µl of plasma without ultracentrifugation.
Amplification of pol and env was performed using an in-house nested PCR protocol. Briefly, 10 µL of the 50 µL RNA extract was subjected to reverse transcription and amplification using the Titan One tube RT-PCR system (Roche, Basel, Switzerland) with a combination of 4 primers. The inner PCR reaction was performed using 2 µL of the outer PCR product and 4 nested primers. Sequencing of the amplicons was performed with the BigDye® Terminator Cycle Sequencing kit v. 3.1 (Life Technologies, Carlsbad, CA, USA) and sequencing products were analyzed on the ABI3130XL Genetic analyzer (Applied Biosystems, Foster City, CA, USA). Chromatograms were checked and edited manually using SmartGene (IDNS™) software (SmartGene GmbH, Zug, Switzerland). Further details on the amplification and sequencing procedures as well as the primer sequences can be obtained from the authors on request.
Ultrasensitive Sanger sequencing
To increase the sensitivity of the Sanger sequencing procedure, the input plasma volume was increased to 1.5 mL and the ultracentrifugation time to 2 hours. The elution volume of the extraction was reduced from 50 µL to 25 µL and 2 µL of MS2 RNA (Roche, Basel, Switzerland) was added as carrier. A 3-step nested amplification protocol was used instead of the standard 2-step reaction as previously described [1] . A detailed description of the PCR conditions can be obtained from the authors on request. Briefly, 20 µL of RNA extract was subjected to 60 minutes of reverse transcription followed by 10 cycles of amplification in a multiplex reaction combining env and pol amplification. Ten µL of the obtained amplicon was then used as input material for two second round 40 cycle amplifications, one with env primers and one with pol primers. Finally, 2 µL of the second round reactions was used as input material for third round 40 cycle amplifications with nested primers.
Next generation sequencing of viral RNA
In-depth env sequencing of viral RNA isolated from the baseline samples was done using the Roche 454 GS Junior next generation sequencing system as described before [24] . Reads were trimmed to 333 nucleotides spanning the env HXB2 nucleotide positions 7,002 to 7,334. In-house software was used to correct errors in homopolymer stretches, using Sanger sequences from each patient as references. Identical reads were clustered and counted. All variants with at least 2 reads and comprising more than 0.2% of the total number of reads were included in phylogenetic analysis.
Single genome sequencing of viral DNA
In-depth env sequencing of PBMC-associated HIV-1 DNA was done using limiting dilution amplification. Briefly, DNA was extracted with the QIAamp Blood Mini kit (Qiagen, Hilden, Germany) from 200 µL of buffy coat and eluted in 200 µL elution buffer according to the manufacturer's instructions. For limiting dilution sequencing, the DNA extract was diluted until no more than 30 to 40% of the nested PCR reactions were positive [25] . Primers and PCR conditions were the same as for the standard Sanger sequencing protocol used to amplify env from plasma RNA, but the reverse transcription step was omitted.
Phylogenetic analysis
All env and pol sequences, from plasma viral RNA and cellular DNA from the different collection points before ART initiation and during the course of LLV, were aligned using MUSCLE software (v3.8.31) [26] . Alignments were manually edited and trimmed to 333 nucleotides for env and 573 nucleotides for pol using BioEdit software (v7.0.9) [27] . Shorter sequences and sequences with stop codons or gaps larger than a nucleotide triplet were removed from the alignments. The best-fitting nucleotide substitution model was selected with jModeltest software (v2.1.7) [28, 29] , using the Akaike Information Criterion (AIC) and phylogenetic trees were inferred using PhyML software (v3.0) [30] . The trees were visualized and rooted using reference sequences from HIV-1 group M subtypes with Mega 6 software (v6.0) [31] . Bootstrap analysis was performed on 100 replicates using PhyML on the E-Biothon platform [32] .
To assess temporal structure in the trees, root-to-tip (RTT) distances were calculated based on the ML phylogeny using TreeStat software (v1.2) and plotted against time [33] . In addition pairwise genetic distances were estimated from the sequence alignment with the Tamura-Nei model as implemented in MEGA 6. To visualize tree expansion over time, temporal tree graphs were constructed using the final maximum likelihood phylogenetic env tree as backbone. Onto this backbone, the sequences from different sampling points were added in a time-dependent order ( Figure 1 ).
Coreceptor tropism analysis
The viral coreceptor tropism was determined using the individual env sequences and the geno2pheno [coreceptor] algorithm [34] . As recommended by the European Consensus Group on clinical management of HIV-1 tropism testing, a false positive rate cut-off of 10% was used for classification as CCR5-or CXCR4-using virus [35] .
Statistical analysis
Linear regression analysis as implemented in SPSS v.22 (IBM, NY, USA) was used to determine if the slopes of the RTT distances and the pairwise distances in function of time significantly differed from zero.
Nucleotide sequence accession numbers
All HIV-1 pol and env sequences derived in this study have been submitted to GenBank and were assigned accession numbers # to # (submission pending).
RESULTS
Patient characteristics
Detailed information on the included patients can be found in Table 1 . The median time of follow-up was 4.8 years (IQR 3.5 -5.6). The median VL at the time of initiation of the ART regimen that resulted in LLV was 5.1 log10 c/mL (IQR 4.9 -5.4) and the median VL during LLV was 51 c/mL (IQR 37 -82; only for the measurements above the detection limit). The minimum duration of LLV at study inclusion (January 2013) was 2.5 years. All patients were infected with subtype B virus, 6 were treatment experienced but had interrupted all medication before initiation of the ART regimen resulting in LLV.
There was no history of drug resistance development. Table 1 .
Amplification and sequencing
Phylogenetic analysis
Maximum likelihood env and pol phylogenetic trees were constructed with all available RNA and DNA sequences after removal of variants with gaps or stop codons. Visual examination of both trees revealed profound per patient clustering except for patients 03 and 17 (Supplemental figure S1).
These two patients were known to be part of a larger MSM transmission cluster, explaining their close genetic homology. No indications for inter-patient contamination during the amplification or sequencing process could be inferred. Detailed phylogenetic trees of env sequences are provided in
If ongoing viral replication occurs during LLV, it is expected that viral variants isolated over time during LLV would show close genetic linkage. Phylogenetic clustering with bootstrap support higher than 70% is an indicator for genetic linkage [36] , therefore clusters fulfilling this criterion were identified and examined for presence of sequences from samples collected during LLV (Table 2 ). Of the 46 and 7 clusters identified respectively in the env and pol trees, 11 and 6 contained at least 2 LLV sequences. For 2 patients (06 and 10) all env LLV sequences were present in a single cluster.
Overall, clusters with 2 or more LLV sequences were detected in 11 patients. They contained LLV sequences sampled over a median period of 2.25 years for env (IQR 0.33 -2.75 years) and 1.71 years for pol (IQR 0.61 -3.82 years). Clusters were either composed uniquely of LLV sequences (patients 07, 15 and 23 for env and patients 01, 05, 14, 18 and 20 for pol) or contained a mixture of pre-ART, LLV RNA and LLV DNA sequences (patients 01, 05, 06, 10 and 11 for env and patient 06 for pol).
Detecting time-dependent evolution
Close genetic linkage of the LLV viruses does not directly imply evolution. To evidence evolution, additional proof of genetic changes building up in a temporal manner must be demonstrated. Visual inspection of env temporal tree graphs clearly revealed absence of evolution in patient 10. For this patient, all obtained env LLV sequences were identical and an identical variant was also present in the baseline plasma sample. In 12 patients (01, 02, 03, 05, 07, 14, 15, 17, 18, 20, 21 and 23) , consecutive addition of LLV sequences resulted in an at random dispersal of these sequences over the tree, intermingled between pre-ART and baseline variants. In 5 patients (06, 09, 11, 19 and 22), the env LLV sequences showed evidence of clustering but there was no association between the position of the LLV sequences in the cluster and the sampling time. Figure 1 shows the expansion of the phylogenetic tree of env sequences through time for 2 representative patients.
Linear regression analysis of the RTT distances of LLV env RNA sequences in function of time revealed significantly increasing RTT distances in patients 07 (p = 0.001) and 15 (p = 0.011) but failed to indicate such a correlation in the other 16 patients. The same analysis performed on the LLV pol sequences showed a significant association between the RTT distances and time in 3 patients (10 (p = 0.032), 18 (p = 0.028) and 22 (p = 0.010)) ( Table 3 ). For the env DNA sequences RTT distance analysis failed to detect any sign of evolution but linear regression analysis of the pairwise distances showed a significant positive slope in 3 patients (05, 14 and 18 (p < 0.001)) and a significant negative slope, suggesting loss of diversity, in 4 patients (03 (p < 0.001), 15 (p < 0.001), 17 (p = 0.002) and 20 (p = 0.034)). For one patient (21) the slope was not significantly different from zero. 
Searching for sequence homology
Coreceptor use during LLV
Consistent CCR5-use over the whole LLV period was observed in 12 of the 18 patients, consistent CXCR4-use in 1 patient (Table 4 ). In the remaining 5 patients, CCR5-using and CXCR4-using variants alternated during LLV. In one patient with alternating CCR5 and CXCR4-use during LLV, only CCR5using variants were detected in the pre-ART and baseline population. Of the 6 patients with a mixed population of CCR5 and CXCR4-using viruses pre-ART and at baseline, alternating detection of CCR5 and CXCR4 variants during LLV was observed in 4.
An overview of the results of all markers of genetic evolution that were analyzed is presented in Table 5 .
DISCUSSION
Patients on ART may present with small amounts of virus in their plasma over a longer period of time without evolution to therapy failure. The source of this virus remains uncertain. In this report we present 18 patients with long-term persisting LLV on ART for whom the virus population was Although the majority of studies attempting to investigate viral replication in patients on ART rely on phylogenetic analysis [7-14, 16, 23] , there is no standard approach on how to reliably evidence genetic evolution. Conclusions are often based on visual inspection of the phylogenetic trees for presence or absence of intermingling of sequences collected at different time points [7-9, 13, 16] .
Alternatively, the most commonly used mathematical methods calculate the divergence (pairwise distances) from the sampled sequences to the inferred most recent common ancestor [10, 11, 23], the RTT distances from the inferred tree [12, 13] , or the overall evolution of pairwise distances between sequences of different sampling points [9, 13, 16, 17] . The identification of genetic evolution following slow rates of virus replication in a background of large overall genetic variability is however challenging. We therefore used a combined approach applying different tools to assess genetic evolution and analyzed two regions of the HIV genome, the more conserved pol gene and the highly variable env gene. Coreceptor use analysis of virus isolated during LLV has, to our knowledge, not been done before.
We used the obtained env sequences to predict the coreceptor preference of the viral isolates. In 6 patients (02, 03, 06, 07, 10, 15) NGS revealed the presence of a mixture of CCR5-and CXCR4-using variants before ART initiation. It was surprising to see that in 3 of these 6 patients (02, 03 and 06) CCR5 and CXCR4-using variants were detected alternately over time during LLV. This finding pleads against viral evolution because in case of evolution and concomitant selective pressure, one would expect the consistent detection of descendants of the same strain with unchanged coreceptor use or possibly a single switch at a certain time point.
So overall we were unable to provide firm arguments for the existence of virus replication and resulting genetic evolution during longer episodes of persistent low viremia under ART. If not virus replication but virus production is considered to be the major contributor to LLV, potential sources of the plasma virus may be long-lived HIV-infected cells continuously releasing virus or latently infected cells that become activated and produce virus before dying [37] . In both cases one would expect considerable intermingling of the sequences from viruses isolated at different time points as well as intermingling of viral RNA and DNA sequences. This intermingling was indeed observed in all 8 patients with both RNA and DNA tested. A hypothesis formulated recently is that the process of stochastic virus production may be driven to a large extent by clonally expanded cells [8, 12, 13, 23] .
Already in 2006, Bailey et al. described the persistence of a predominant plasma clone in patients on
ART with a viral load <50 c/mL [8] . More recently, integration site analysis provided further compelling evidence for the presence of clonally expanded HIV-infected cells in vivo [38] [39] [40] . In 11 of the 18 patients we observed identical RNA sequences at different time points during LLV, often spread over a long time span, supporting the idea of production from clonally expanded cells.
However, the origin of these predominant plasma sequences could be traced to the cellular compartment only in 2 patients, indicating that the producing cells do not constitute the majority of infected cells in the blood.
Whether clonally expanded cells are capable of producing replication competent virus remains a subject of debate [41, 42] . There are indications that a large majority of proviruses in these expanded cell clones is defective [12, 38, 39, 42] . But Simonetti et al. recently showed a highly expanded CD4+ T cell clone carrying replication competent provirus in 1 patient and Kearney et al. found that in 2 patients who underwent treatment interruption the origin of rebound plasma virus was an expanded cell clone [43, 44] . Whether patients with higher numbers of clonally expanded cells are more prone to LLV under ART is a hypothesis that needs to be investigated further.
A drawback of our study is that only bulk sequencing was performed on the plasma samples collected during LLV. As a result, it is likely that only the most represented variant is sequenced and this may have reduced the sensitivity to detect evolution over time. Ambiguous nucleotide positions were detected at 1 or more positions in 59 of the 143 env sequences, an indication that in these cases a mixture of variants was present. Another shortcoming is that the env phylogenetic analysis was performed on short sequences because of the limited read length of the NGS. Recently, Laskey et al. showed that sequence identity in subgenomic regions of the viral genome does not guarantee clonality across the full viral genome [45] . So although we sequenced a highly variable part of the env gene we cannot exclude missing some diversity.
The median sequencing depth of our NGS analysis was 596 reads per patient. This was considered sufficient for a global estimate of the viral variability and to characterize the most represented viral strains at initiation of ART, which was the goal of the analysis. Low-frequent viral variants will be missed, but this will not impact the conclusions regarding viral evolution during LLV as this conclusion is based on the phylogenetic relationship between the LLV sequences.
CONCLUSIONS
Taken together, the results of this study failed to support presence of active virus replication and evolution in patients with LLV above the detection limits of commercial assays while being on ART.
This finding is in line with our previous observations that in the majority of cases of LLV on ART we could not document treatment failure or drug resistance [1] . Today, about 3 years after closure of sample inclusion, 10 of the 18 study patients still present recurrent LLV. Eight patients have evolved to a continuously undetectable viral load (<20 c/mL), 6 of them without ART changes and 2 after a treatment adaptation. None of the 18 patients has developed virologic failure or drug resistance.
All these observations support the hypothesis that residual viremia mainly results from a process of virus production. It is however important to emphasize that, although generally used for these purposes, the power of phylogenetic analysis to exclude very low levels of virus replication may be limited. Absence of evidence is therefore not necessarily evidence of absence and future research should concentrate on the development of alternative methods for the detection or exclusion of active replication in the presence of ART. 
X, CXCR4-tropic virus; R, CCR5-tropic virus LLV1 to 12: consecutive sampling, time interval differs between patients
